Ginkgo bioworks acquires proof diagnostics, growing gene editing service offerings for its customers

Boston , feb. 28, 2024 /prnewswire/ -- today, ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, announced the acquisition of proof diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases. proof was founded by gene editing pioneer dr. feng zhang of the broad institute of mit and harvard, drs.
DNA Ratings Summary
DNA Quant Ranking